Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    M5A08
Previous Study | Return to List | Next Study

Retrospective Survey of Safety of Fourth Dose Pentacel® in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00772369
Recruitment Status : Completed
First Posted : October 15, 2008
Results First Posted : April 2, 2010
Last Update Posted : February 14, 2014
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Study Type Observational
Study Design Observational Model: Cohort;   Time Perspective: Retrospective
Conditions Diphtheria
Pertussis
Haemophilus Infection
Tetanus
Polio
Enrollment 3214
Recruitment Details Telephone contact for this study was from 20 September 2003 to 30 April 2004.
Pre-assignment Details A total of 3214 participants that met the inclusion and exclusion criteria were enrolled in this survey. One participant did not return a record release form and twenty-nine (29) others were also excluded from the Primary Analysis Population because their safety data could not be confirmed.
Arm/Group Title Study Group
Hide Arm/Group Description Received 4th dose of the Pentacel® series before 2nd birthday
Period Title: Overall Study
Started 3214
Completed 3213
Not Completed 1
Reason Not Completed
Did not return record release form             1
Arm/Group Title Study Group
Hide Arm/Group Description Received 4th dose of the Pentacel® series before 2nd birthday
Overall Number of Baseline Participants 3214
Hide Baseline Analysis Population Description
[Not Specified]
Age, Categorical  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 3214 participants
<=18 years
3214
 100.0%
Between 18 and 65 years
0
   0.0%
>=65 years
0
   0.0%
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Months
Number Analyzed 3214 participants
19.5  (1.45)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 3214 participants
Female
1538
  47.9%
Male
1676
  52.1%
Region of Enrollment  
Measure Type: Number
Unit of measure:  Participants
Canada Number Analyzed 3214 participants
3214
1.Primary Outcome
Title Number of Participants Who Had Positive Response to the Solicited Adverse Events Questionnaire Post 4th Dose of the Pentacel® Vaccination Series
Hide Description

Positive response is a 'Yes' to any of the following questions:

  1. Has your child been admitted to a hospital?
  2. Has your child experienced an illness that made you fear for his/her life (life-threatening episode) that required attendance to the Emergency Room or a Physician’s office?
  3. Has your child developed a medical condition that required 3 or more office or emergency room visits for that condition?
  4. Has your child been diagnosed by a physician as having:

Low blood count or low platelet count? Swelling or redness of the joints? Asthma? Diabetes? Autism?

Time Frame 6 months post 4th dose vaccination
Hide Outcome Measure Data
Hide Analysis Population Description
Participants who completed the whole survey. Those who had confirmed data, or had data that did not require confirmation, or had unconfirmed data.
Arm/Group Title Study Group
Hide Arm/Group Description:
Received 4th dose of the Pentacel® series before 2nd birthday
Overall Number of Participants Analyzed 3213
Measure Type: Number
Unit of Measure: Particpants
Participants with no events reported 3023
Participants with events reported and confirmed 161
Events at 0 to 180 days after Dose 4 149
Events after Day 180 only 6
Events prior to Dose 4 only 6
Participants with events not confirmed 29
2.Primary Outcome
Title Number of Participants Reporting Serious Adverse Events (SAE) Post 4th Dose of the Pentacel® Vaccination Series and Relationship to Study Vaccine.
Hide Description

SAE: any untoward medical occurrence with the following outcomes:

  • death,
  • a life-threatening adverse drug experience (as confirmed by the investigators),
  • inpatient hospitalization or prolongation of existing hospitalization,
  • a persistent or significant disability/incapacity, or
  • a congenital anomaly/birth defect. Medical conditions that required 3 or more office or emergency room visits, and diagnosis by a physician of low blood cell count or low platelet count, swelling or redness of the joints, asthma, diabetes, or autism were also solicited. (MedDRA Version 6.0)
Time Frame 6 Months post 4th dose vaccination
Hide Outcome Measure Data
Hide Analysis Population Description
Response to questionnaire that were confirmed by the primary care physician’s office were analyzed, Primary Analysis Population. Unconfirmed safety data form 29 participants were excluded from the primary analysis.
Arm/Group Title Study Group
Hide Arm/Group Description:
Received 4th dose of the Pentacel® series before 2nd birthday
Overall Number of Participants Analyzed 3184
Measure Type: Number
Unit of Measure: Participants
SAEs Occurring Post-dose 4 (Any) 80
SAEs Occurring Post-dose 4 (Related) 6
Red cell aplasia (Any) 1
Red cell aplasia (Related) 1
Vomiting nos (Any) 3
Vomiting nos (Related) 1
Difficulty in walking (Any) 1
Difficulty in walking (Related) 0
Pyrexia (Any) 2
Pyrexia (Related) 1
Hypersensitivity nos (Any) 1
Hypersensitivity nos (Related) 1
Bronchiolitis (Any) 3
Bronchiolitis (Related) 0
Bronchitis viral (Any) 1
Bronchitis viral (Related) 0
Bronchopneumonia nos (Any) 2
Bronchopneumonia nos (Related) 0
Cellulitis (Any) 1
Cellulitis (Related) 0
Croup infectious (Any) 8
Croup infectious (Related) 0
Gastroenteritis nos (Any) 6
Gastroenteritis nos (Related) 0
Gastroenteritis rotavirus (Any) 2
Gastroenteritis rotavirus (Related) 0
Gastroenteritis viral nos (Any) 2
Gastroenteritis viral nos (Related) 0
Herpes zoster (Any) 1
Herpes zoster (Related) 0
Kawasaki's disease (Any) 3
Kawasaki's disease (Related) 1
Lobar pneumonia nos (Any) 2
Lobar pneumonia nos (Related) 0
Localised infection (Any) 1
Localised infection (Related) 0
Periorbital cellulitis (Any) 1
Periorbital cellulitis (Related) 0
Pharyngitis (Any) 1
Pharyngitis (Related) 0
Pneumonia nos (Any) 7
Pneumonia nos (Related) 0
Pneumonia viral nos (Any) 1
Pneumonia viral nos (Related) 0
Tonsillitis viral nos (Any) 1
Tonsillitis viral nos (Related) 0
Upper respiratory tract infection nos (Any) 1
Upper respiratory tract infection nos (Related) 0
Urinary tract infection nos (Any) 1
Urinary tract infection nos (Related) 0
Viral infection nos (Any) 3
Viral infection nos (Related) 0
Femur fracture (Any) 1
Femur fracture (Related) 0
Hip dislocation (Any) 1
Hip dislocation (Related) 0
Diabetes mellitus nos (Any) 1
Diabetes mellitus nos (Related) 0
Acute lymphocytic leukaemia (Any) 1
Acute lymphocytic leukaemia (Related) 0
Autism (Any) 1
Autism (Related) 0
Convulsions nos (Any) 2
Convulsions nos (Related) 0
Febrile convulsion (Any) 13
Febrile convulsion (Related) 1
Breath holding (Any) 1
Breath holding (Related) 0
Balanitis nos (Any) 1
Balanitis nos (Related) 0
Asthma nos (Any) 8
Asthma nos (Related) 0
Bronchitis nos (Any) 1
Bronchitis nos (Related) 0
Pneumonia aspiration (Any) 1
Pneumonia aspiration (Related) 1
Wheezing (Any) 1
Wheezing (Related) 0
Time Frame Safety data were solicited through a retrospective survey within 6 months of the post-4th dose of Pentacel™ vaccine.
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title Study Group
Hide Arm/Group Description Received 4th dose of the Pentacel® series before 2nd birthday
All-Cause Mortality
Study Group
Affected / at Risk (%)
Total   --/--    
Show Serious Adverse Events Hide Serious Adverse Events
Study Group
Affected / at Risk (%) # Events
Total   93/3213 (2.89%)    
Blood and lymphatic system disorders   
Blood and lymphatic system disorders  1  1/3213 (0.03%)  1
Gastrointestinal disorders   
Gastrointestinal disorders  1  6/3213 (0.19%)  7
General disorders   
General disorders and administration site conditions  1  4/3213 (0.12%)  4
Immune system disorders   
Immune system disorders  1  2/3213 (0.06%)  2
Infections and infestations   
Infections and infestations  1  52/3213 (1.62%)  52
Injury, poisoning and procedural complications   
Injury, poisoning and procedural complication  1  2/3213 (0.06%)  2
Metabolism and nutrition disorders   
Metabolism and nutrition disorders  1  2/3213 (0.06%)  2
Neoplasms benign, malignant and unspecified (incl cysts and polyps)   
Neoplasms benign, malignant and unspecified (incl cysts and polyps)  1  1/3213 (0.03%)  1
Nervous system disorders   
Nervous system disorders  1  18/3213 (0.56%)  19
Psychiatric disorders   
Psychiatric disorders  1  2/3213 (0.06%)  3
Reproductive system and breast disorders   
Reproductive system and breast disorders  1  1/3213 (0.03%)  1
Respiratory, thoracic and mediastinal disorders   
Respiratory, thoracic and mediastinal disorders  1  12/3213 (0.37%)  13
Surgical and medical procedures   
Surgical and medical procedures  1  1/3213 (0.03%)  2
Indicates events were collected by systematic assessment
1
Term from vocabulary, MedDRA 6.0
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Study Group
Affected / at Risk (%) # Events
Total   0/3123 (0.00%)    
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.
Results Point of Contact
Name/Title: Medical Director
Organization: Sanofi Pasteur Inc.
Responsible Party: Sanofi ( Sanofi Pasteur, a Sanofi Company )
ClinicalTrials.gov Identifier: NCT00772369     History of Changes
Other Study ID Numbers: M5A08
First Submitted: October 13, 2008
First Posted: October 15, 2008
Results First Submitted: March 15, 2010
Results First Posted: April 2, 2010
Last Update Posted: February 14, 2014